Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid
Novozymes Biopharma, part of Novozymes announced the construction of a new cGMP facility at the company's existing site in Tianjin, China that will enable its novel form of Bacillus-based Hyaluronic Acid (bHA), HyaCare, to be used within the bio-medical and pharmaceutical industries.

With a significant investment of over DKK 300 million, this new facility will produce bHA products to pharmaceutical grade Q7, paving the way for use in medical devices and pharmaceutical applications.
"The strategic decision to build this new facility was based on a thorough market review and the increasing demand for bHA. Regulators are ever more cautious with regards to the safety of products and so a cGMP compliant facility is an essential part of our strategy in bringing bHA forward for use in medical device and pharmaceutical applications," comments Hans Ole Klingenberg, Director, Novozymes Biopharma. "China was an obvious choice as we already have a world-class manufacturing operation there with more than 20 years experience. This site will also facilitate expansion as business opportunities develop."
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.